1,888
Views
3
CrossRef citations to date
0
Altmetric
Clinical Study

Thromboelastography versus bleeding time for risk of bleeding post native kidney biopsy

, , , , , , & ORCID Icon show all
Pages 10-18 | Received 23 Jul 2019, Accepted 22 Nov 2019, Published online: 16 Dec 2019

References

  • Appel GB. Renal biopsy: how effective, what technique, and how safe. J Nephrol. 1993;6:4–9.
  • Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant. 1994;9:1255–1259.
  • Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis. 2000;35:448–457.
  • Madaio MP. Renal biopsy. Kidney Int. 1990;38:529–543.
  • Atwell TD, Spanbauer JC, McMenomy BP, et al. The timing and presentation of major hemorrhage after 18,947 image-guided percutaneous biopsies. Am J Roentgenol. 2015;205:190–195.
  • Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci. 1998;316:94–104.
  • Gawaz MP, Dobos G, Späth M, et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol. 1994;5:36–46.
  • Sohal AS, Gangji AS, Crowther MA, et al. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res. 2006;118:417–422.
  • Ho SJ, Gemmell R, Brighton TA. Platelet function testing in uremic patients. Hematology. 2008;13:49–58.
  • ParrIsh AE. Complications of percutaneous renal biopsy: a review of 37 years’ experience. Chin Nephrol. 1992;38:135–141.
  • Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979;7:107–117.
  • Lind SE. The bleeding time does not predict surgical bleeding. Blood. 1991;77:2547–2552.
  • Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16:1–20.
  • Mattix H, Singh AK. Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? Curr Opin Nephrol Hypertens. 1999;8:715–718.
  • Lehman CM, Blaylock RC, Alexander DP, et al. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem. 2001;47:1204–1211.
  • Lin WC, Yang Y, Wen YK, et al. Outpatient versus inpatient renal biopsy: a retrospective study. Clin Nephrol. 2006;66:17–24.
  • Nass K, O'Neill WC. Bedside renal biopsy: ultrasound guidance by the nephrologist. Am J Kidney Dis. 1999;34:955–959.
  • Diaz-Buxo JA, Donadio JV Jr. Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. Clin Nephrol. 1975;4:223–227.
  • Stratta P, Canavese C, Marengo M, et al. Risk management of renal biopsy: 1387 cases over 30 years in a single centre. Eur J Clin Invest. 2007;37:954–963.
  • Waldo B, Korbet SM, Freimanis MG, et al. The value of post-biopsy ultrasound in predicting complications after percutaneous renal biopsy of native kidneys. Nephrol Dial Transplant. 2009;24:2433–2439.
  • Korbet SM, Volpini KC, Whittier WL. Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies. Am J Nephrol. 2014;39:153–162.
  • Stiles KP, Hill C, LeBrun CJ, et al. The impact of bleeding times on major complication rates after percutaneous real-time ultrasound-guided renal biopsies. J Nephrol. 2001;14:275–279.
  • Manno C, Strippoli GF, Arnesano L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int. 2004;66:1570–1577.
  • Whittier WL, Korbet SM. Renal biopsy: update. Curr Opin Nephrol Hypertens. 2004;13:661–665.
  • Islam N, Fulop T, Zsom L, et al. Do platelet function analyzer-100 testing results correlate with bleeding events after percutaneous renal biopsy? Clin Nephrol. 2010;73:229–237.
  • Kuiper G, Christiaans MHL, Mullens M, et al. Routine haemostasis testing before transplanted kidney biopsy: a cohort study. Transpl Int. 2018;31:302–312.
  • Hartert H. Blood coagulation studies using thromboelastography: a new evaluation technique. Klin Wochenschr. 1948;26:577–583.
  • Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014;89:228–232.
  • De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology. 2016;63:566–573.
  • Spiess BD, Tuman KJ, McCarthy RJ, et al. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monitor Comput. 1987;3:25–30.
  • Darlington A, Ferreiro JL, Ueno M, et al. Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost. 2011;106:67–74.
  • Davis CL, Chandler WL. Thromboelastography for the prediction of bleeding after transplant renal biopsy. J Am Soc Nephrol. 1995;6:1250–1255.
  • Levey AS, Stevens LA, Schmid CH, Zhang YL, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
  • Cotton BA, Faz G, Hatch QM, et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma. 2011;71:407–414.
  • Huang MJ, Wei R, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open. 2017;7:e014294.
  • Pivalizza EG, Abramson DC, Harvey A. Perioperative hypercoagulability in uremic patients: a viscoelastic study. J Clin Anesth. 1997;9:442–445.
  • Pandey CK, Saluja V, Gaurav K, et al. K time & maximum amplitude of thromboelastogram predict post-central venous cannulation bleeding in patients with cirrhosis: a pilot study. Indian J Med Res. 2017;145:84–89.
  • Thakur M, Ahmed A. A review of thromboelastography. IJPUT. 2012;1:25–29.
  • Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol. 2004;15:142–147.
  • Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60:62–73.
  • Korbet SM. Percutaneous renal biopsy. Semin Nephrol. 2002;22:254–267.
  • Shidham GB, Siddiqi N, Beres JA, et al. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton). 2005;10:305–310.
  • Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol. 2005;9:40–45.
  • Whittier WL, Sayeed K, Korbet SM. Clinical factors influencing the decision to transfuse after percutaneous native kidney biopsy. Clin Kidney J. 2016;9:102–107.
  • Simard-Meilleur MC, Troyanov S, Roy L, et al. Risk factors and timing of native kidney biopsy complications. Nephron Extra. 2014;4:42–49.
  • Augusto JF, Lassalle V, Fillatre P, et al. Safety and diagnostic yield of renal biopsy in the intensive care unit. Intensive Care Med. 2012;38:1826–1833.
  • Xu DM, Chen M, Zhou FD, et al. Risk factors for severe bleeding complications in percutaneous renal biopsy. Am J Med Sci. 2017;353:230–235.
  • Manno C, Bonifati C, Torres DD, et al. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011;57:850–855.